ARTICULUS BIO TO PRESENT AT 10TH ANNUAL BIOTECH SHOWCASE CONFERENCE DURING JP MORGAN HEALTHCARE WEEK
By: Colorado BioScience Association Date: 01/08/2018
Articulus Bio, LLC, a development-stage orthopedic medical device platform focused on total joint replacement, today announced that Adam B. Rubenstein, Chief Executive Officer, will present at the 10th annual Biotech Showcase Conference on Wednesday, January 10, 2018, at 3:15 p.m. PST. The conference is being held at the Hilton Union Square Hotel in San Francisco, California.
About Articulus Bio, LLC
Articulus Bio, LLC is a development-stage orthopedic medical device platform focused on total joint replacement. Our novel Tendonoid™ Web Joint technology addresses the problem at the heart of total joint replacement failures: polyethylene particulate wear debris. In vivo degradation of prosthetic implant materials is increasingly recognized as a major factor limiting the durability of total joint arthroplasty. The poly-wear shedding occurs at articulating faces of the appliances caused by grinding, sliding and friction from natural anatomical motion. An immunological cascade is catalyzed by the wear particles that stimulates osteolysis, an adverse local host response, leading to periprosthetic bone loss that compromises implant fixation and bone stock, typically ending in device failure. The Articulus Bio Tendonoid™ Web Joint technology engineers out the friction inducing grinding and sliding thereby eliminating wear debris. In addition, personalized 3D print geometries, customized jigs, individualized ranges of motion, and proven surfacing techniques contribute to improved bone/device bond integrity, reduced bone/blood loss, improved surgical positioning and decreased OR time. Pipeline product candidates include total ankle replacement device and cervical/lumbar spine artificial discs. For more information please visit www.articulusbio.com